ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 1279

Whole Blood Gene Expression Defined Subgroups of Treatment Naïve Children and Adolescents with Childhood-onset Systemic Lupus Erythematosus.
Abstract Number: 1280

Investigating the Association Between SARS-CoV-2 Infection, COVID-19 Vaccination, and Autoimmune Diseases in a Pediatric Population: A comprehensive analysis
Abstract Number: 1281

Ethnic Disparities in Mental Health Screening, Diagnoses, and Outcomes in Patients with Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 1282

Real-world use of belimumab in childhood-onset SLE in Spain: cross-sectional analysis from a multicenter study (JULES registry)
Abstract Number: 1283

Impact of Guideline Concordant Care of Renal Outcomes in Childhood-Onset Lupus Nephritis
Abstract Number: 1284

Clinical implications of Antiphospholipid Antibodies and Secondary Antiphospholipid Syndrome in Juvenile-onset Systemic Lupus Erythematosus
Abstract Number: 1285

Investigating the Relationship Between Brain Injury Markers and Brain Volume in Children with Systemic Lupus Erythematosus and Healthy Controls
Abstract Number: 1286

Response to Hydroxychloroquine in Immune Thrombocytopenia in Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 1287

A clear pattern of clinical presentation in juvenile systemic scleroderma is associated with interstitial lung disease
Abstract Number: 1288

Is gastroesophageal reflux a risk for interstitial lung disease in Juvenile systemic sclerosis?
Abstract Number: 1289

Longitudinal Exploration of Pain and Disease Characteristics in Youth with Childhood-Onset Lupus
Abstract Number: 1290

Adverse Childhood Experiences: Prevalence and Relationship to Disease and Mental Health Outcomes in Childhood-Onset Systemic Lupus Erythematosus (cSLE)
Abstract Number: 1291

Gastrointestinal Tract Involvement in Juvenile Systemic Sclerosis: Results from an International Scoping Review of Outcome Measures
Abstract Number: 1292

Childhood-onset Behçet’s disease: HLA alleles role on diagnosis and treatment in a Latin American tertiary center
Abstract Number: 1293

Synovitis and periarticular soft tissues abnormalities in childhood-onset systemic lupus erythematosus: an ultrasonography study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].